Interventional Cardiovascular Surgery

Yohei Ohno provides his takeaways from the results of the MATTERHORN trial presented by Volker Rudolph at the ESC Congress 2024 in London.

Discover the risks and benefits of TAVI in patients with low surgical risk, building on the data of the latest randomised trial in this field, the DEDICATE trial, of which Moritz Seiffert was one of the leading investigators.

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.

The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.

The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.

This session focuses on the management of non-ST-elevation myocardial infarction (NSTEMI) in patients who have previously undergone coronary artery bypass grafting (CABG). Attendees will explore various case presentations and discussions on the challenges and treatment strategies for this complex clinical scenario, including the use of intravascular...

Maurizio Taramasso interviews Ottavio Alfieri, a pioneering figure in valve surgery and a key contributor to the development of transcatheter edge-to-edge repair, honored with the Ethica Award at the 2024 edition of #europcr. Ottavio Alfieri discusses his journey to becoming a cardiac surgeon, the genesis of...

This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.

Luigi Biasco interviews Moritz Seiffert about the one-year outcomes of the randomized DEDICATE-DZHK6 trial which he presented at ACC.24 in Atlanta.

TAVR was found non-inferior to SAVR in low-risk patients, showing decreased rates of death or stroke at one year. The trial supports TAVR's safety and efficacy, highlighting...

Two cardiac surgeons, Hendrik Treede and Michael Reardon, and an echo specialist, Joao Cavalcante, have been invited to share their views on aortic regurgitation management.

So far, surgery remains the gold standard, and they explain why, by also comparing repair and replacement, before discussing the challenge that...